People started on a low dose of Amgen's long-acting experimental obesity drug MariTide lost as much weight as those given ...

CHICAGO -- Mifepristone (Korlym) reduced HbA1c levels in patients with inadequately controlled type 2 diabetes and ...

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

A protocol designed for primary care increased weight loss across a quarter of a million people, but only 25% of those with a ...

Shares of Amgen (AMGN) fell on Monday after announcing that its weight-loss drug will move into a phase 3 trial, with ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

Casino workers, labor leaders and public health advocates have been pushing to add casinos to the state's indoor smoking ban ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.